Cancer and Metastasis Reviews

, Volume 24, Issue 1, pp 47–69 | Cite as

Biological significance of c-erbB family oncogenes in head and neck cancer

  • Susanne J. Rogers
  • Kevin J. Harrington
  • Peter Rhys-Evans
  • Pornchai O-Charoenrat
  • Suzanne A. Eccles


Squamous cell carcinoma of the head and neck (SCCHN) tends to run an aggressive course and the prognosis has remained virtually unchanged in recent decades. The development of novel therapeutic strategies to improve patient outcome centres on the biology of the disease, namely the pivotal c-erbB family of growth factor receptors. c-erbB1 (or epidermal growth factor receptor, EGFR), is key to the pathogenesis of SCCHN and plays a central role in a complex network of downstream integrated signalling pathways. EGFR overexpression, detected in up to 90% of SCCHN, correlates with an increased risk of locoregional tumour relapse following primary therapy and relative resistance to treatment. The biological sequelae of erbB receptor activation are not simply cell proliferation, but also inhibition of apoptosis, enhanced migration, invasion, angiogenesis and metastasis: the ‘hallmarks of cancer’ [1]. As EGFR overexpression is associated with a poor clinical outcome in SCCHN, this receptor is attractive as a therapeutic target and the successful development of targeted therapies represents a paradigm shift in the medical approach to head and neck cancer. However, the extensive cross talk between signalling pathways, the multiple molecular aberrations and genetic plasticity in SCCHN all contribute to inherent and acquired resistance to both conventional and novel therapies. Understanding the cancer cell biology, in particular the significance of co-expression of c-erbB (and other) receptors, and the cell survival stimuli from (for example) activation of the phosphoinositide 3-kinase (PI3-kinase) cascade is fundamental to overcome current limitations in biologically targeted therapies.


c-erbB oncogenes squamous cell carcinoma head and neck cancer metastasis invasion angiogenesis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100: 57–70, 2000CrossRefPubMedGoogle Scholar
  2. 2.
    Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, Demard F, Milano G: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11: 1873–1878, 1993PubMedGoogle Scholar
  3. 3.
    Kusukawa J, Harada H, Shima I, Sasaguri Y, Kameyama T, Morimatsu M: The significance of epidermal growth factor receptor and matrix metalloproteinase 3 in squamous cell carcinoma of the oral cavity. Oral Oncol 32: 217–221, 1996Google Scholar
  4. 4.
    Klapper LN, Kirschbaum MH, Sela M, Yarden Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77: 25–79, 2000PubMedCrossRefGoogle Scholar
  5. 5.
    Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 284: 99–110, 2003PubMedGoogle Scholar
  6. 6.
    Barnes CJ, Kumar R: Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets. Cancer Met Rev 22: 301–307, 2003Google Scholar
  7. 7.
    Schlessinger J: Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110: 669–722, 2002PubMedGoogle Scholar
  8. 8.
    O-charoenrat P, Rhys-Evans P, Modjtahedi H, Eccles SA: The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral Oncol 38: 627–650, 2002PubMedGoogle Scholar
  9. 9.
    Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307: 521–527, 1984PubMedGoogle Scholar
  10. 10.
    Grandis JR, Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579–3584, 1993PubMedGoogle Scholar
  11. 11.
    Shin DM, Ro JY, Hong WK, Hittelman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 3153–3159, 1994PubMedGoogle Scholar
  12. 12.
    Grandis JR, Tweardy DJ, Melhem MF: Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 4: 13–20, 1998Google Scholar
  13. 13.
    Grandis JR, Zeng Q, Drenning SD: Epidermal growth factor receptor-mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope 110: 868–874, 2000Google Scholar
  14. 14.
    Ibrahim SO, Vasstrand EN, Liavaag PG, Johannessen AC, Lillehaug JR: Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res 17: 4539–4546, 1997PubMedGoogle Scholar
  15. 15.
    Werkmeister R, Brandt B, Joos U: Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol 36: 100–105, 2000PubMedGoogle Scholar
  16. 16.
    Wilkman TS, Heitanen JH, Malstrom MJ, Kontiinen YT: Immunohistochemical analysis of the oncoprotein c-erbB-2 expression in oral benign and malignant lesions. Int J Oral Maxillofac Surg 27: 209–212, 1998PubMedGoogle Scholar
  17. 17.
    Chen Z, Zhang K, Zhang X, Yuan XH, Yuan Z, Jin L, Xiong M: Comparison of gene expression between metastatic derivatives and their poorly metastatic parental cells implicates crucial tumor-environment interaction in metastasis of head and neck squamous cell carcinoma. Clin Exp Metastasis 20: 335–342, 2003PubMedGoogle Scholar
  18. 18.
    Ulanovski D, Stern Y, Roizman P, Shpitzer T, Popovtzer A, Feinmesser R: Expression of EGFR and c-erbB-2 as prognostic factors in cancer of the tongue. Oral Oncol 40: 532–537, 2004PubMedGoogle Scholar
  19. 19.
    Zhu HJ, Iaria J, Orchard S, Walker F, Burgess AW: Epidermal growth factor receptor: Association of extracellular domain negatively regulates intracellular kinase activation in the absence of ligand. Growth Factors, 21: 15–30, 2003Google Scholar
  20. 20.
    Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 647–655, 1997Google Scholar
  21. 21.
    Hellyer NJ, Kim MS, Koland JG: Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor. J Biol Chem 276: 42153–42161, 2001PubMedGoogle Scholar
  22. 22.
    Hou L, Shi D, Tu SM, Zhang HZ, Hung MC, Ling D: Oral cancer progression and c-erbB-2/neu proto-oncogene expression. Cancer Lett 65: 215–220,1992PubMedGoogle Scholar
  23. 23.
    Bei R, Pompa G, Vitolo D, Moriconi E, Ciocci L, Quaranta M, Frati L, Kraus MH, Muraro R: Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma. J Pathol 195: 343–348, 2001PubMedGoogle Scholar
  24. 24.
    Sakurai K, Urade M, Takahashi Y, Takahashi Y, Kishimoto H, Noguchi K, Yasoshima H, Kubota A: Increased expression of c-erbB-3 protein and proliferating cell nuclear antigen during development of verruccous carcinoma of the oral mucosa. Cancer 89: 2597–2605, 2000PubMedGoogle Scholar
  25. 25.
    Xia W, Lau Y-K, Zhang H-Z, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL, Hung MC: Combination of EGFR, HER-2/neu and -3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5: 4164–4174, 1999PubMedGoogle Scholar
  26. 26.
    O-charoenrat P, Rhys-Evans P, Eccles S: Characterisation of ten newly-derived human head and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression. Anticancer Res 21: 1953–1964, 2001PubMedGoogle Scholar
  27. 27.
    O-charoenrat P, Rhys-Evans PH, Archer DJ, Eccles SA: c-erbB receptors in squamous cell carcinomas of the head and neck: Clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 38: 73–80, 2002PubMedGoogle Scholar
  28. 28.
    Kamer AR, Sacks PG, Vladutiu A, Liebow C: EGF mediates multiple signals: dependence on the conditions. Int J Mol Med 13: 143–147, 2004PubMedGoogle Scholar
  29. 29.
    Shirasuna K, Hayashido Y, Sugiyama M, Yoshioka H, Matsuya T: Immunohistochemical localization of epidermal growth factor (EGF) and EGF receptor in human oral mucosa and its malignancy. Virchows Arch A Pathol Anat Histopathol 418: 349–353, 1991PubMedGoogle Scholar
  30. 30.
    Issing WJ, Liebich C, Wustrow TP, Ullrich A: Coexpression of epidermal growth factor receptor and TGF-alpha and survival in upper aerodigestive tract cancer. Anticancer Res 16: 283–288, 1996PubMedGoogle Scholar
  31. 31.
    Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ: Levels of TGFα and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824–832, 1998Google Scholar
  32. 32.
    O-charoenrat P, Rhys-Evans P, Modjtahedi H, Court W, Box G, Eccles S: Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer 86: 307–317, 2000PubMedGoogle Scholar
  33. 33.
    O-charoenrat P, Rhys-Evans P, Court W, Box G, Eccles SA: Differential modulation of proliferation, matrix metalloproteinase expression and invasion of human head and neck squamous carcinoma cells by c-erbB ligands. Clin Exp Metastasis 17: 631–639, 1999PubMedGoogle Scholar
  34. 34.
    O-charoenrat P, Modjtahedi H, Rhys-Evans P, Court W, Box GM, Eccles SA: Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 60: 1121–1128, 2000PubMedGoogle Scholar
  35. 35.
    Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y: ErbB2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. MBO J 15: 254–264, 1996Google Scholar
  36. 36.
    Weiss FU, Wallasch C, Campiglio M, Issing W, Ullrich A: Distinct characteristics of heregulin signals mediated by HER3 or HER4. J Cell Physiol 173: 187–195, 1997PubMedGoogle Scholar
  37. 37.
    Massague J, Pandiella A: Membrane-anchored growth factors. Annu Rev Biochem 62: 515–541, 1993PubMedGoogle Scholar
  38. 38.
    O-charoenrat P, Rhys-Evans, P, Eccles S: A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops. Int J Cancer 100: 527–533, 2002PubMedGoogle Scholar
  39. 39.
    Motoyama AB, Hynes NE, Lane HA: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62: 3151–3158, 2002PubMedGoogle Scholar
  40. 40.
    Fischer OM, Hart S, Gschwind A, Ullrich A: EGFR signal transactivation in cancer cells. Biochem Soc Trans 31: 1203–1208, 2003PubMedCrossRefGoogle Scholar
  41. 41.
    Wetzker R, Bohmer FD: Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat Rev Molec Cell Biol 4: 651–657, 2003Google Scholar
  42. 42.
    Guerrero J, Santibanez JF, Gonzalez A, Martinez G: EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. Exp Cell Res 292: 201–208, 2004PubMedGoogle Scholar
  43. 43.
    Kato Y, Chao TH, Hayashi M, Tapping RI, Lee JD: Role of BMK1 in regulation of growth factor-induced cellular responses. Immunol Res 21: 233–237, 2000PubMedGoogle Scholar
  44. 44.
    Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD: Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395: 713–716, 1998CrossRefPubMedGoogle Scholar
  45. 45.
    Zhong Z, Wen Z, Darnell JE: Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95–98, 1994PubMedGoogle Scholar
  46. 46.
    Bromberg J, Darnell JE: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468–2473, 2000PubMedGoogle Scholar
  47. 47.
    Xi S, Zhang Q, Gooding WE, Smithgall TE, Grandis JR: Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res 63: 6763–6771, 2003PubMedGoogle Scholar
  48. 48.
    Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, Xi S, Grandis JR: STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 13: 355–362, 2002PubMedGoogle Scholar
  49. 49.
    Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS: Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63: 2948–2956, 2003PubMedGoogle Scholar
  50. 50.
    Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE: ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 274: 17209–17218, 1999PubMedGoogle Scholar
  51. 51.
    Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J Clin Invest 102: 1385–1392, 1998CrossRefPubMedGoogle Scholar
  52. 52.
    Battle TE, Frank DA: The role of STATs in apoptosis. Curr Mol Med 2: 381–392, 2002PubMedGoogle Scholar
  53. 53.
    Huang S, Bucana CD, Arsdall M, Fidler IJ: Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 21: 2504–2412, 2002PubMedGoogle Scholar
  54. 54.
    Luo J, Manning BD, Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257–262, 2003CrossRefPubMedGoogle Scholar
  55. 55.
    Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489–501, 2002PubMedGoogle Scholar
  56. 56.
    Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240–4245,1999PubMedGoogle Scholar
  57. 57.
    Chen Q, Samaranayake LP, Zhou H, Xiao L: Homozygous deletion of the PTEN tumor-suppressor gene is not a feature in oral squamous cell carcinoma. Oral Oncol 36: 95–99, 2000PubMedGoogle Scholar
  58. 58.
    Mavros A, Hahn M, Wieland I, Koy S, Koufaki ON, Strelocke K, Koch R, Haroske G, Schackert HK, Eckelt U: Infrequent genetic alterations of the tumor suppressor gene PTEN/MMAC1 in squamous cell carcinoma of the oral cavity. J Oral Pathol Med 31: 270–276, 2002PubMedGoogle Scholar
  59. 59.
    Shin KH, Kim JM, Rho KS, Park KH, Oh JE, Min BM: Inactivation of the PTEN gene by mutation, exonic deletion, and loss of transcript in human oral squamous cell carcinomas. Int J Oncol 21: 997–1001, 2002PubMedGoogle Scholar
  60. 60.
    She Q-B, Solit D, Basso A, Moasser M: Resistance to gefitinib in PTEN-null-HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacological modulation of constitutive phosphatidylinositol 3’-kinase/Akt pathway signalling. Clin Cancer Res 9: 4340–4346, 2003Google Scholar
  61. 61.
    Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812–2822, 2003CrossRefPubMedGoogle Scholar
  62. 62.
    Worsham MJ, Pals G, Schouten JP, van Spaendonk RML, Concus A, Carey TE, Benninger MS: Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 129: 702–708, 2003PubMedGoogle Scholar
  63. 63.
    Manning BD, Cantley LC: United at last: The tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans 31: 573–578, 2003PubMedGoogle Scholar
  64. 64.
    Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC: Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597–601,1999CrossRefPubMedGoogle Scholar
  65. 65.
    Guba M, Von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nature Med 8: 128–135, 2002PubMedGoogle Scholar
  66. 66.
    Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM: Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 64: 55–63, 2004PubMedGoogle Scholar
  67. 67.
    Rodrigo JP, Suarez C, Ferlito A, Davaney KO, Petruzzelli J, Rinaldo A: Potential molecular prognostic markers for lymph node metastasis in head and neck squamous cell carcinoma. Acta Otolaryngol 123: 100–105, 2003PubMedGoogle Scholar
  68. 68.
    Comoglio PM, Boccaccio C, Trusolino L: Interactions between growth factor receptors and adhesion molecules: Breaking the rules. Curr Opin Cell Biol 15: 565–571, 2003PubMedGoogle Scholar
  69. 69.
    Ponta H, Sherman L, Herrlich PA: CD44: From adhesion molecules to signalling regulators. Nat Rev Molec Cell Biol 4: 33–45, 2003Google Scholar
  70. 70.
    Shiozaki H, Kadowaki T, Doki Y, Inoue M, Tamura S, Oka H, Iwazawa T, Matsui S, Shimaya K, Takeichi M: Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line. Br J Cancer 71: 250–258, 1995PubMedGoogle Scholar
  71. 71.
    Genersch E, Schneider DW, Sauer G, Khazaie K, Schuppan D, Lichtner RB: Prevention of EGF-modulated adhesion of tumor cells to matrix proteins by specific EGF receptor inhibition. Int J Cancer 75: 205–209, 1998PubMedGoogle Scholar
  72. 72.
    Shintani S, Li C, Mihara M, Nakashiro K, Hamakawa H: Gefitinib (Iressa) an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells. Cancer Lett 201: 149–155, 2003PubMedGoogle Scholar
  73. 73.
    Chen P, Xie H, Sekar MC, Gupta, Wells A: Epidermal growth factor receptor-mediated cell motility: Phospholipase C activity is required, but mitogen activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol 127: 847–857 1994CrossRefPubMedGoogle Scholar
  74. 74.
    Xie H, Pallero MA, Gupta K Chang P, Ware MF, Witke W, Kwiatkowski DJ, Lauffenberger DA, Murphy-Ullrich JE, Wells A: EGF receptor regulation of cell motility: EGF disassembly of focal adhesions independently of the motility-associated PLC gamma signalling pathway. J Cell Sci 111: 615–624, 1998PubMedGoogle Scholar
  75. 75.
    Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD, Grandis JR: Epidermal growth factor receptor-stimulated activation of phospholipase C gamma-1 promotes invasion of head and neck squamous cell carcinoma. Cancer Res 63: 5629–5635, 2003PubMedGoogle Scholar
  76. 76.
    Chen P, Murphy-Ullrich JE, Wells A: A role for gelsonin in actuating epidermal growth factor receptor-mediated cell motility. J Cell Biol 137: 481–492, 1996Google Scholar
  77. 77.
    Tang J, Gross DJ: Regulated EGF receptor binding to F-actin modulates receptor phosphorylation. Biochem Biophys Res Commun 312: 930–936, 2003PubMedGoogle Scholar
  78. 78.
    Marriotti A, Kedeshian PA, Dans M, Curatola AM, Gagnoux-Palacios L, Giancotti FG: EGF-R signalling through Fyn kinase disrupts the function of integrin α 6β 4 at hemidesmosomes: Role in epithelial cell migration and carcinoma invasion. J Cell Biol 155: 447–458, 2001CrossRefPubMedGoogle Scholar
  79. 79.
    Gambaletta D, Marchetti A, Benedetti L, Mercurio AM, Sacchi A, Falconi R: Co-operative signalling between α6β4 integrin and erbB-2 receptor is required to promote phosphatidylinositol 3-kinase dependent invasion. J Biol Chem 275: 10604–10610, 2000PubMedGoogle Scholar
  80. 80.
    Wells A, Grandis JR: PhospholipaseC-γ 1 in tumour progression. Clin Exp Metastasis 20: 285–290, 2003PubMedGoogle Scholar
  81. 81.
    Ridley AJ, Hall A: The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70: 389–399, 1992CrossRefPubMedGoogle Scholar
  82. 82.
    Kundra V, Escobedo JA, Kazlauskas A, Kim HK, Rhee SG, Williams LT, Zetter BR: Regulation of chemotaxis by the platelet-derived growth factor receptor-beta. Nature 367: 474–476, 1994PubMedGoogle Scholar
  83. 83.
    Yang Z, Bagheri-Yarmand R, Wang R-A, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R: The epidermal growth factor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 10: 658–667, 2004PubMedGoogle Scholar
  84. 84.
    Eccles SA: Cell biology of lymphatic metastasis: The potential role of c-erbB oncogene signalling. Recent Res Cancer Res 157: 41–54, 2000Google Scholar
  85. 85.
    Elenius K, Paul S, Allison G, Sun J, Klagsbrun M: Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 16: 1268–1278 1997PubMedGoogle Scholar
  86. 86.
    Eccles S: Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention in cancer. Int J Dev Biol (in press) 2004Google Scholar
  87. 87.
    Polette M, Clavel C, Muller D, Abecassis J, Binninger I, Birembaut P: Detection of mRNAs encoding collagenase I and stromelysin 2 in carcinoma of head and neck by in situ hybridisation. Invasion Metastasis 11: 76–83, 1991PubMedGoogle Scholar
  88. 88.
    Muller D, Wolf C, Abecassis J, Millon R, Engelmann A, Bronner G, Rouyer N, Rio MC, Eber M, Methlin G: Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res 53: 165–169, 1993PubMedGoogle Scholar
  89. 89.
    Kawamata H, Nakashiro K, Uchida D, Harada K, Yoshida H, Sato M: Possible contribution of active MMP2 to lymph-node metastasis and secreted cathepsin L to bone invasion of newly established human oral-squamous-cancer cell lines. Int J Cancer 70: 20–27, 1997Google Scholar
  90. 90.
    Johansson N, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U, Kahari VM: Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 151: 499–508, 1997PubMedGoogle Scholar
  91. 91.
    Yu D, Hamada J, Zhand H, Nicolson GL, Hung MC: Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 7: 2263–2270, 1992PubMedGoogle Scholar
  92. 92.
    O-charoenrat P, Rhys-Evans P, Eccles SA: Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 127: 813–820, 2001PubMedGoogle Scholar
  93. 93.
    Sahin U, Weskamp G, Kelly K, Zhou H-M, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel CP: Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164: 769–779, 2004CrossRefPubMedGoogle Scholar
  94. 94.
    McCawley LJ, Matrisian LM: Matrix metalloproteinases: Multifunctional contributors to tumor progression. Molec Med Today 6: 149–156, 2000Google Scholar
  95. 95.
    O-charoenrat P, Wongkajornsilp A, Rhys-Evans P, Eccles SA: Signaling pathways required for matrix metalloproteinase-9 induction by betacellulin in head and neck squamous carcinoma cells. Int J Cancer (in press) 2004Google Scholar
  96. 96.
    Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F, Pontes JE, Crissman JC, Fridman R: High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56: 1654–1659, 1996PubMedGoogle Scholar
  97. 97.
    Rhee JS, Diaz R, Korets L, Hodgson JG, Coussens LM: TIMP-1 alters susceptibility to carcinogenesis. Cancer Res 64: 952–961, 2004PubMedGoogle Scholar
  98. 98.
    Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401–410, 2003CrossRefPubMedGoogle Scholar
  99. 99.
    Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669–676, 2003CrossRefPubMedGoogle Scholar
  100. 100.
    Homer JJ, Greenman J, Stafford ND: Angiogenesis in head and neck squamous cell carcinoma. Clin. Otolaryngol 25: 169–180, 2000PubMedGoogle Scholar
  101. 101.
    Petruzzelli GJ, Benefield J, Taitz AD, Fowler S, Kalkanis J, Scobercea S, West D, Young MR: Heparin-binding growth factor(s) derived from head and neck squamous cell carcinomas induce endothelial cell proliferation. Head Neck 19: 576–582, 1997PubMedGoogle Scholar
  102. 102.
    Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG: Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18: 2046–2052, 2000PubMedGoogle Scholar
  103. 103.
    Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15: 290–298, 1996PubMedGoogle Scholar
  104. 104.
    Partanen TA, Alitalo K, Miettinen M: Lack of lymphatic vascular specificity of endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 86: 2406–2412, 1999PubMedGoogle Scholar
  105. 105.
    Beasley N, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, Harris AL: Hypoxia-inducible factors HIF1α and HIF2α in head and neck cancer. Cancer Res 62: 2493–2497, 2002PubMedGoogle Scholar
  106. 106.
    Gille J, Swerlick RA, Caughman SW: Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 16: 750–759, 1997PubMedGoogle Scholar
  107. 107.
    Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C, Van Waes C: Effects of pharmacological antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κ B and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous carcinoma cell lines. Int J Cancer 99: 538–548, 2002PubMedGoogle Scholar
  108. 108.
    Brader S, O-Charoenrat P, Court W, Box G, Workman P, Eccles S: Signalling pathways in afferent and efferent arms of angiogenesis induced by activation of c-erbB receptors. Proc Am Assoc Cancer Res 43:(abstract #168) 33, 2002Google Scholar
  109. 109.
    Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000–2008, 2002PubMedGoogle Scholar
  110. 110.
    Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151: 1523–1530, 1997PubMedGoogle Scholar
  111. 111.
    O-charoenrat P, Rhys-Evans P, Modjtahedi H, Eccles SA: Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 18: 155–161, 2000PubMedGoogle Scholar
  112. 112.
    Nakashima T, Hudson JM, Clayman GL: Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma. Head Neck 22: 483–488, 2000PubMedGoogle Scholar
  113. 113.
    Baker CH, Kedar D, McCarty MF, Tsan R, Weber KL, Bucana CD, Fidler IJ: Blockade of epidermal growth factor receptor signalling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 161: 929–938, 2002PubMedGoogle Scholar
  114. 114.
    Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K: Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16: 3898–3911, 1997PubMedGoogle Scholar
  115. 115.
    Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol 2: 737–744, 2000PubMedGoogle Scholar
  116. 116.
    Kalluri R: Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3: 422–433, 2003PubMedGoogle Scholar
  117. 117.
    Van Trappen PO, Pepper MS: Lymphatic dissemination of tumour cells and the formation of micrometastases. Lancet Oncol 3: 44–52, 2002PubMedGoogle Scholar
  118. 118.
    Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K: Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61: 1786–1790, 2001PubMedGoogle Scholar
  119. 119.
    Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186–191, 2001PubMedGoogle Scholar
  120. 120.
    Alitalo K, Carmeliet P: Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1: 219–227, 2002PubMedGoogle Scholar
  121. 121.
    Saaristo A, Partanen TA, Arola J, Jussila L, Hytonen M, Makitie A, Vento S, Kaipainen A, Malmberg H, Alitalo K: Vascular endothelial growth factor-C and its receptor VEGFR-3 in the nasal mucosa and in nasopharyngeal tumors. Am J Pathol 157: 7–14, 2000PubMedGoogle Scholar
  122. 122.
    O-charoenrat, P Rhys-Evans P, Eccles, SA: Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 92: 556–568, 2001PubMedGoogle Scholar
  123. 123.
    Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62: 7350–7356, 2002Google Scholar
  124. 124.
    Liang K, Ang KK, Milas L, Hunter N, Fan Z: The epidermal growth factor receptor mediates radioresistance. Int J Radiation Oncol Biol Phys 57: 246–254, 2003Google Scholar
  125. 125.
    Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich RK: Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen activated protein kinase pathway in carcinoma cells, leading to increased cell proliferation and protection from radiation–induced cell death. Mol Biol Cell 10: 2493–2506, 1999PubMedGoogle Scholar
  126. 126.
    Schmidt-Ullrich RK, Contessa JN, Lammering G, Amorino G, Lin P-S: ErbB receptor tyrosine kinases and cellular radiation responses. Oncogene 22: 5855–5865, 2003PubMedGoogle Scholar
  127. 127.
    McKenna WG, Muschel RJ: Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer 38: 330–338, 2003PubMedGoogle Scholar
  128. 128.
    Amorino GP, Hamilton VM Valerie K, Dent P, Lammering G, Schmidt-Ullrich RK: Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast cancer cells. Mol Biol Cell 13: 2233–2244, 2002PubMedGoogle Scholar
  129. 129.
    Shintani S, Li C, Mihara M, Terakado N, Yano J, Nakashiro K, Hamakawa H: Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839) and epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 107: 1 030–1037, 2003PubMedGoogle Scholar
  130. 130.
    Holsinger FC, Doan DD, Jasser SA, Swan EA, Greenberg JS, Schiff BA, Bekele BN, Younes MN, Bucana CD, Fidler IJ, Myers JN: Epidermal growth factor receptor blockade potentiates apoptosis mediated by paclitaxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 9: 3183–3189, 2003PubMedGoogle Scholar
  131. 131.
    Huang SM, Li J, Armstrong EA, Harari PM: Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1939 (Iressa). Cancer Res 62: 4300–4306, 2002PubMedGoogle Scholar
  132. 132.
    Niwa H, Wentzel AL, Li M, Gooding WE, Lui V, Grandis JR: Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin Cancer Res 9: 5028–5035, 2003PubMedGoogle Scholar
  133. 133.
    Viloria-Petit AM, Kerbel RS: Acquired resistance to EGFR inhibitors: Mechanisms and prevention strategies. Int J Radiation Oncol Biol Phys 58: 914–926, 2004Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Susanne J. Rogers
    • 1
    • 2
  • Kevin J. Harrington
    • 2
    • 3
  • Peter Rhys-Evans
    • 2
  • Pornchai O-Charoenrat
    • 1
    • 2
    • 4
  • Suzanne A. Eccles
    • 1
  1. 1.Tumour Biology and Metastasis Team, CRUK Centre for Cancer Therapeutics, McElwain LaboratoriesInstitute for Cancer ResearchSurrey
  2. 2.Head and Neck UnitRoyal Marsden HospitalLondon
  3. 3.Targeted Therapy Team, Section of Cell and Molecular BiologyChester Beatty LaboratoriesLondonUK
  4. 4.Division of Head, Neck & Breast Surgery, Department of SurgerySiriraj Hospital Medical SchoolBangkokThailand

Personalised recommendations